Details of the Drug Combination

General Information of Drug Combination (ID: DC332FF)

• Drug Combination Name: Olodaterol + BI-54903
• Indication: Asthma; Status: Phase 1 [1]
• Component Drugs:
  Olodaterol (DM62B78): Small molecular drug
  BI-54903 (DM6D1G6): N.A.

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Olodaterol

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Approved	[2]

Olodaterol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Modulator	[4]

Olodaterol Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[5]

Indication(s) of BI-54903

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[3]

References

• [1] ClinicalTrials.gov (NCT01428622) Olodaterol Bridging Study in Asthma. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7543).
• [3] ClinicalTrials.gov (NCT01397201) Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS). U.S. National Institutes of Health.
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] FDA Label of Olodaterol. The 2020 official website of the U.S. Food and Drug Administration.